Authors Details

Immune checkpoint inhibitors (ICIs) are now a standard of care for many cancers. Unfortunately, their cost is still prohibitively high for many patients in low- and middle-income countries (LMICs). In this large Indian study, the authors found that short-course ICIs had similar efficacy and safety profiles in South Asian patients as those seen in other ethnicities and countries. This may thus encourage the use of ICIs in LMICs.